Showing 3871-3880 of 4063 results for "".
- Phase 3 Data for BF-200 ALA Presented at the 14th South Beach Symposiumhttps://practicaldermatology.com/news/phase-3-data-for-bf-200-ala-presented-at-the-14th-south-beach-symposium/2458702/Biofrontera AG’s BF-200 ALA plus red light photodynamic therapy (PDT) shows good efficacy for the treatment of actinic keratoses (AK), according to data presented from three pivotal Phase III trials at the 14th Annual South Beach Symposium. The results were presented in a poster (Poster #11
- Hilary Baldwin, MD, Named Medical Director of ATRChttps://practicaldermatology.com/news/hilary-baldwin-md-named-medical-director-of-atrc/2458710/The newly opened Acne Treatment and Research Center (ATRC) in Morristown, NJ, has tapped Hilary Baldwin, MD, to serve as its medical director. Dr. Baldwin received her BA and MA in biology from Boston Uni
- Novan Announces Robert A. Ingram as Chairmanhttps://practicaldermatology.com/news/novan-announces-robert-a-ingram-as-chairman/2458716/Novan, Inc. named Robert A. Ingram as Chairman of the Board of Directors of Novan. In addition, Robert Keegan has been appointed to the Board of Directors. The company also announced that it received $32.8 million of net proceeds in a private Mezzanine B financing in December 2015 from it
- Vyome Biosciences: FDA Has Accepted IND for Investigational Acne Therapyhttps://practicaldermatology.com/news/vyome-biosciences-fda-has-accepted-ind-for-investigational-acne-therapy/2458728/The FDA has accepted from Vyome Biosciences an Investigational New Drug (IND) Application for the initiation of clinical studies for its lead program VB 1953, a topical therapeutic candidate for the treatment of moderate-to-severe acne. Vyome plans to start the Phase I clinical trials very soon.<
- Is Pregnancy-Associated Melanoma More Lethal? Study Says Yeshttps://practicaldermatology.com/news/is-pregnancy-associated-melanoma-more-lethal-study-says-yes/2458744/Women who develop melanoma during their pregnancy or within one year of it are more likely to die from the disease, a new study suggests. Specifically, women diagnosed with malignant melanoma during their pregnancy or within one year of giving birth were 5.1-times as likely to die, 6.9-ti
- Data: EpiDuo Forte Shows Benefit in Severe Inflammatory Acnehttps://practicaldermatology.com/news/data-epiduo-forte-shows-benefit-in-severe-inflammatory-acne/2458743/New data suggest that Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5% from Galderma, recently approved for the treatment of moderate to severe acne vulgaris, may have benefit for the topical treatment of severe inflammatory acne. Data published for the in the Dece
- Concern About Zika Virus in US Set to Escalatehttps://practicaldermatology.com/news/concern-about-zika-virus-in-us-set-to-escalate/2458751/U.S dermatologists may start to receive calls from patients who are concerned about infection with Zika virus – particularly pregnant ones. Zika is now spreading rapidly across Latin America and the Caribbean. So far, one case has been identified in Houston, but the possibility
- New Blood Test Gets Leg Up On Advanced Melanomahttps://practicaldermatology.com/news/new-blood-test-gets-leg-up-on-advanced-melanoma/2458756/A blood test that monitors blood levels of DNA fragments from dead cancer cells may be better at tracking progression of metastatic melanoma than the current standard blood test. The standard test measures blood levels of the enzyme lactate dehydrogenase (LDH), which tend t
- Oculus Innovative Sciences Receives FDA Clearance for Microcyn-Based SebDerm Gelhttps://practicaldermatology.com/news/oculus-innovative-sciences-receives-fda-clearance-for-microcyn-based-sebderm-gel/2458780/Oculus Innovative Sciences, Inc. received a new 510(k) clearance from the FDA for the company’s new Microcyn®-based SebDerm Gel. As a prescription product, SebDerm Gel is intended to manage and relieve the burning, itching, erythema, scaling, and pain experienced with seborrh
- FDA Grants ReCell Expedited Access Pathway Designation to Treat Burnshttps://practicaldermatology.com/news/fda-grants-recell-expedited-access-pathway-designation-to-treat-burns/2458782/The FDA has ruled that the ReCell® Autologous Cell Harvesting Device from Avita Medical Ltd. is eligible for earlier regulatory approval for burns treatment. The ruling came under new FDA guidelines called the Expedited Access Pathway (EAP), which are aimed at helping patients get mor